Replimune Group, Inc – a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies – ...

Engagement with FDA on GH001 IND complete response ongoingThe fully completed Open-Label Extension analysis confirms a 73% remission rate at 6 months with infrequent treatment visits and no ...

The head of the U.S. Department of Veterans Affairs (VA) is reiterating that he’s “very open” to expanding access to ...

Oncoustics Oncoustics initiates FDA study of the OnX Liver Assessment Solution at clinical sites across the US and Canada marking a milesto ...

Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space ...